2. Summary of Significant Accounting Policies (Details - Percentage breakdown)		12 Months Ended
		Apr. 30, 2021		Apr. 30, 2020		Apr. 30, 2019
Halozyme Therapeutics, Inc [Member]
Customer revenue as a percentage of revenue		51.00%		28.00%		30.00%
Gilead Sciences, Inc. [Member]
Customer revenue as a percentage of revenue		16.00%		24.00%
Acumen Pharmaceuticals, Inc. [Member]
Customer revenue as a percentage of revenue			[1]	11.00%			[1]
IGM Biosciences, Inc. [Member]
Customer revenue as a percentage of revenue			[1]	11.00%			[1]
Coherus BioSciences, Inc.
Customer revenue as a percentage of revenue	[1]
ADC Therapeutics America [Member]
Customer revenue as a percentage of revenue			[1]		[1]	21.00%
Coherus Biosciences, Inc. [Member]
Customer revenue as a percentage of revenue				10.00%		13.00%

[1] Represents a percentage less than 10% of our total revenues.